Laryngeal Dysfunction Following COVID‐19: A TriNetX Retrospective Cohort Study Authors: Cali Loblundo, Warren B. Chun, Shaun A. Nguyen, Kirsten Meenan, Ashli K. O'Rourke Published: 2026 ABSTRACT ABSTRACTObjective(s)Long COVID affects multiple organ systems, yet the incidence and risk factors for post–COVID‐19 laryngeal dysfunction remain underexplored. This study evaluated the incidence of laryngeal dysfunction following COVID‐19.MethodsA retrospective cohort study was performed using the TriNetX Global Collaborative EHR Network (> 180 million records). Adults without prior laryngeal dysfunction or major comorbidities were stratified by COVID‐19 exposure and compared with uninfected controls. Outcomes included chronic cough, dysphagia, voice disorders, vocal fold paralysis, and laryngeal spasm, assessed up to 5 years post‐infection. After propensity score matching, odds ratios (OR) and risk differences (RD) with 95% confidence intervals (CI) were calculated.ResultsCOVID‐19 was associated with significantly increased odds of chronic cough (peak OR 7.12; RD 0.33%, p < 0.0001), dysphagia (peak OR 2.71; RD 0.36%, p < 0.0001), voice disorders (peak OR 3.25; RD 0.12%, p < 0.0001), vocal fold paralysis (peak OR 2.17; RD 0.01%, p < 0.0001), and laryngeal spasm (peak OR 2.79; RD 0.003%, p < 0.0001). Incidence peaked at 1–2 years for most outcomes and at 2–3 years for laryngeal spasm. Hospitalization and mechanical ventilation were associated with increased rates of dysphagia (HR 2.63; HR 5.26), voice disorders (HR 1.15; HR 4.45), and vocal cord paralysis (HR 2.09; HR 9.35), but reduced rates of chronic cough (HR 0.68; HR 0.45). Vaccinated patients showed higher rates of chronic cough (HR 1.36) and voice disorders (HR 1.22).ConclusionCOVID‐19 is associated with increased incidence of new‐onset laryngeal dysfunction, most commonly peaking 1–2 years after infection and influenced by hospitalization, mechanical ventilation, and vaccination status.Level of Evidence3. Introduction Since its emergence in late 2019, coronavirus disease 2019 (COVID‐19), caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), has become a major global public health crisis, with over 676 million confirmed infections and at least 7 million reported deaths worldwide [1, 2]. Beyond direct mortality, COVID‐19 has strained healthcare delivery systems, exacerbated health disparities, and contributed to an estimated 15 million excess deaths in its initial years [3, 4]. The resulting clinical and societal burden continues to shape medical, economic, and social landscapes worldwide. A substantial proportion of individuals experience persistent or recurrent symptoms following SARS‐CoV‐2 infection, a syndrome termed “long COVID” or post‐acute sequelae of SARS‐CoV‐2 infection (PASC) [5, 6, 7]. Long COVID encompasses a wide spectrum of manifestations affecting multiple organ systems, with fatigue, dyspnea, cognitive impairment, sleep disturbances, and musculoskeletal pain among the most common symptoms [8, 9, 10]. Increasing evidence indicates that COVID‐19 may cause persistent dysfunction of the larynx and related structures, manifesting as chronic cough, dysphonia, dysphagia, vocal cord immobility, and other voice or swallowing abnormalities [11, 12, 13]. Proposed mechanisms include direct viral neurotropism, local inflammation, airway trauma, and post‐intensive care syndrome [11, 14]. Laryngeal dysfunction following COVID‐19 has been reported in both hospitalized and non‐hospitalized populations, although risk factors, mechanisms, and predominant clinical presentations may differ [12, 14]. In hospitalized patients, studies describe high rates of dysphagia, dysphonia, vocal fold motion impairment, and airway stenosis, with severity related to ICU duration and time intubated [14, 15, 16]. These sequelae are thought to arise from ICU‐acquired weakness, instrumentation‐related trauma, and laryngotracheal mucosa injury from direct mechanical compression, often leading to long‐lasting impairment [12, 17, 18]. Non‐hospitalized and non‐intubated patients report chronic cough, vocal fatigue, and dysphagia [12, 19, 20, 21]. The pathophysiology is likely driven by systemic inflammation, neurotropism (e.g., direct viral involvement of neural tissue) and post‐viral neuropathy (e.g., dysfunction persisting after infection resolution) [12, 22, 23, 24]. In non‐hospitalized cohorts, up to 44% report dysphonia and up to 17% dysphagia, suggesting that laryngeal sequelae extend beyond patients exposed to invasive airway interventions [12, 19, 20]. Although prior work links COVID‐19 to long‐term laryngeal dysfunction, the overall incidence and temporal trends in large, population‐based samples remain poorly quantified. Leveraging the TriNetX Global Collaborative EHR Network, this retrospective study estimates the incidence and evolution of newly diagnosed laryngeal disorders following COVID‐19 compared to matched controls. Despite limitations inherent to observational data and retrospective design, this approach is intended to clarify temporal trends and risk factors for post‐COVID laryngeal sequelae and inform future prospective investigations. Materials and Methods A retrospective cohort study was conducted utilizing the TriNetX Global Collaborative Network [25], a federated platform that provides access to de‐identified electronic health records (EHRs) from healthcare organizations (HCOs) internationally. As of November 26, 2025, the Global Collaborative Network comprised 165 participating HCOs, encompassing 187,866,743 patient records. TriNetX operates with de‐identified data complying with the Health Insurance Portability and Accountability Act (HIPAA) Privacy Rule. Because this study only used de‐identified aggregate data, institutional review board (IRB) approval was not required. Baseline Cohorts Adults aged ≥ 18 years were included. Cohorts were defined using the following codes: current procedural terminology (CPT), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD‐10‐CM), Logical Observation Identifiers Names and Codes (LOINC), and Systematized Nomenclature of Medicine, Clinical Terms (SNOMED CT). Two cohorts were generated: (1) patients with documented history of COVID‐19, identified using ICD‐10‐CM U07.1, and (2) patients without history of COVID‐19 recorded in the network. To minimize confounding factors, identical exclusion criteria were applied to both cohorts. Inclusion and exclusion criteria were applied before matching and outcome analysis. Inclusion and exclusion criteria are listed in Table 1. TABLE 1Diagnostic codes used for cohort identification, exclusion criteria, and outcome determination.Diagnostic codes utilized for patient selection and outcome analysisUse within studyCodeCondition/VariableInclusion criteriaICD‐10‐CM U07.1COVID‐19 InfectionExclusion criteriaG47.33History of obstructive sleep apneaJ40‐J4AChronic lower respiratory diseasesC34Malignant neoplasm of the bronchus or lungZ72.0Tobacco useLOINC 72166–2Tobacco smoking statusZ71.6Tobacco abuse counselingO99.33Tobacco use disorder complicating pregnancy, childbirth, or the puerperiumF17Nicotine dependenceF10Alcohol‐related disordersC00‐C14Malignant neoplasms of the lip, oral cavity, and pharynxC76.0Malignant neoplasm of the head, face, and neckC31Malignant neoplasm of the accessory sinusesC32Malignant neoplasm of the larynxCPT 1009025; SNOMED 118766009History of thyroid surgery or proceduresOutcomesR05.3Chronic coughR13Aphagia and dysphagiaR49Voice and resonance disordersJ38.0Paralysis of vocal cords and larynxJ38.5Laryngeal spasm Note: Current procedural terminology (CPT), international classification of diseases, tenth revision, clinical modification (ICD‐10‐CM), logical observation identifiers names and codes (LOINC), and systematized nomenclature of medicine, clinical terms (SNOMED CT) codes were applied to define inclusion and exclusion criteria and to identify laryngeal outcomes of interest within the study cohort. Diagnostic codes used for cohort identification, exclusion criteria, and outcome determination. Note: Current procedural terminology (CPT), international classification of diseases, tenth revision, clinical modification (ICD‐10‐CM), logical observation identifiers names and codes (LOINC), and systematized nomenclature of medicine, clinical terms (SNOMED CT) codes were applied to define inclusion and exclusion criteria and to identify laryngeal outcomes of interest within the study cohort. Outcome Measures Outcomes were compared between baseline cohorts with and without a history of COVID‐19. Outcomes of interest included incidence of newly diagnosed laryngeal dysfunction, identified using ICD‐10‐CM codes: chronic cough (R05.3), aphagia and dysphagia (R13), voice and resonance disorders (R49), paralysis of vocal cords and larynx (J38.0), and laryngeal spasm (J38.5). The term “aphagia”, conventionally denoting absence of swallowing, was included in the search strategy because it is commonly used in clinical billing to refer broadly to dysphagia, helping avoid inadvertent exclusion of relevant cases. Codes in this paragraph are paired with their common clinical billing descriptors. For clarity we use the following simplified terms throughout the study: dysphagia for “aphagia and dysphagia”, voice disorder for “voice and resonance disorder”, and vocal cord paralysis for “paralysis of vocal cords and larynx.” Outcome coding is listed in Table 1. Biostatistics Analyses were performed using de‐identified data within the TriNetX Global Collaborative Network [25] and its integrated Analytics platform, which automatically calculated incidence proportions, odds ratios (ORs), hazard ratios (HRs), and 95% confidence intervals (CIs). Baseline characteristics were summarized using means with standard deviations for continuous variables and proportions for categorical variables. To minimize differences between cohorts, propensity score matching was applied using a nearest‐neighbor approach with a fixed caliper, and covariate balance was assessed using standardized mean differences, with values < 0.10 considered acceptable [26, 27]. Patients with pre‐existing diagnoses of the outcome of interest were excluded. Incidence proportions and interval‐specific associations were assessed across five post‐index periods (0–1, 1–2, 2–3, 3–4, and 4–5 years) using logistic regression, with ORs and 95% CIs reported [28]. Time‐to‐event analyses were conducted within the platform to evaluate cumulative risk over 5 years, with HRs and 95% CIs automatically generated. Kaplan–Meier curves were constructed, and proportional hazards assumptions were verified using Schoenfeld residuals [29, 30]. Subgroup analyses explored heterogeneity within the COVID‐19 cohort by vaccination status, hospitalization, and mechanical ventilation; sub‐cohorts were propensity score‐matched on demographic characteristics, and HRs were visualized using forest plots. All statistical tests were two‐sided, with a p < 0.05 considered statistically significant. A flowchart displaying methodology is shown in Figure 1. Flowchart showing study design and cohort selection workflow. Adults ≥ 18 years were identified by ICD‐coded COVID‐19 diagnosis and matched 1:1 by propensity score based on age at index to controls identified by any ICD code. Exclusion criteria, subgroup analyses, and evaluated laryngeal outcomes, including chronic cough, aphagia or dysphagia, voice or resonance disorders, paralysis of vocal cords or larynx, and laryngeal spasm, are shown. Results Baseline Cohort Characteristics Before propensity score matching, the COVID‐19 cohort (n = 1,983,078) differed demographically from the non–COVID‐19 cohort (n = 49,636,889). Individuals with documented COVID‐19 were older on average (49.6 ± 18.8 years) compared with those without infection (44.3 ± 18.3 years). COVID‐19 cohort also had a higher proportion of females (60.6% vs. 55.6%). Ethnic distributions showed similar patterns across groups, although the COVID‐19 cohort had a slightly higher proportion of Hispanic or Latino individuals than the non‐COVID‐19 group (10.5% vs. 9.6%). Racial distributions also differed between cohorts, with the non‐infection cohort having lower proportions of White (59.5% vs. 65.7%) and Black or African American patients (13.1% vs. 14.5%) compared to the infection cohort (Tables 2 and S1). TABLE 2Baseline demographic characteristics of patients diagnosed with COVID‐19 infection and controls without COVID‐19 diagnosis prior to propensity score matching.Demographic characteristics of COVID‐19 diagnosis cohort vs. control cohort before propensity score matchingCOVID‐19 diagnosis cohort (n = 1,983,078)Non‐COVID‐19 control cohort (n = 49,636,889)Age (years) a 49.6 ± 18.844.3 ± 18.3SexFemale1,202,580 (60.6)26,974,597 (55.6)Male778,920 (39.3)20,408,648 (42.1)Unknown1576 (0.1)1,105,181 (2.3)EthnicityHispanic or Latino208,665 (10.5)4,637,878 (9.6)Not Hispanic or Latino1,383,949 (69.8)30,197,503 (62.3)Unknown ethnicity390,462 (19.7)13,653,045 (28.2)RaceWhite1,303,402 (65.7)28,830,713 (59.5)Black or African American286,830 (14.5)6,350,244 (13.1)Asian97,356 (4.9)2,355,142 (4.9)Native Hawaiian or Other Pacific Islander11,419 (0.6)258,284 (0.5)American Indian or Alaska Native9022 (0.5)160,985 (0.3)Unknown RACE148,435 (7.5)7,692,898 (15.9)Other race126,612 (6.4)2,840,160 (5.9) Note: Categorical variables are presented as counts with corresponding percentages shown in parentheses. a Age is reported as mean ± standard deviation. Baseline demographic characteristics of patients diagnosed with COVID‐19 infection and controls without COVID‐19 diagnosis prior to propensity score matching. Note: Categorical variables are presented as counts with corresponding percentages shown in parentheses. Age is reported as mean ± standard deviation. Primary Outcome Analysis Following propensity score matching, the COVID‐19 cohort showed a higher likelihood of developing chronic cough across all evaluated time intervals. Odds were elevated from 0 to 1 years (OR 5.64; 95% CI 5.38–5.84; p < 0.0001). Highest odds were seen during the 1–2 years period (OR 7.12; 95% CI 6.68–7.60; p < 0.0001), with lower but still elevated risk continuing in the 2–3 years time frame (OR 6.43; 95% CI 6.00–6.90; p < 0.0001). Although declining, elevated odds persisted through 3–4 years (OR 3.97; 95% CI 3.67–4.29; p < 0.0001), with modest odds still present at 4–5 years (OR 1.22; 95% CI 1.11–1.34; p < 0.0001). Risk differences mirrored these trends, gradually decreasing from 0.63% in the first year to 0.01% by year five. COVID‐19 patients showed increased odds of dysphagia during the first 4 years after infection. Odds were elevated at 0–1 years (OR 1.58; 95% CI 1.55–1.61; p < 0.0001), peaked at 1–2 years (OR 2.71; 95% CI 2.62–2.81; p < 0.0001) and remained elevated through the 2–3‐years time frame (OR 2.44; 95% CI 2.34–2.54; p < 0.0001). Odds declined in the 3–4‐years period (OR 1.69; 95% CI 1.61–1.78; p < 0.0001) with a reversal of odds ratios being seen in the 4–5‐years period (OR 0.68; 95% CI 0.64–0.83; p < 0.0001). Voice disorders showed significantly increased odds in the COVID‐19 cohort during the first 4 years of follow‐up. Odds were slightly elevated from 0 to 1 years (OR 1.18; 95% CI 1.14–1.23; p < 0.0001), followed by highest risk being observed at 1–2 years (OR 3.25; 95% CI 3.03–3.48; p < 0.0001). Odds were lower but still elevated at 2–3 years (OR 2.75; 95% CI 2.55–2.98; p < 0.0001) and 3–4 years (OR 1.94; 95% CI 1.77–2.12; p < 0.0001). By 4–5 years, odds fell below baseline (OR 0.7; 95% CI 0.68–0.86; p < 0.0001), with a small negative risk difference. Associations between COVID‐19 and vocal cord paralysis varied over time. A reduced odds ratio was seen at 0–1‐years (OR 0.72; 95% CI 0.65–0.79; p < 0.0001) with a small negative risk difference. This was followed by significantly elevated odds at 1–2‐years (OR 2.17; 95% CI 1.79–2.64; p < 0.0001) and 2–3‐years (OR 1.94; 95% CI 1.55–2.41; p < 0.0001), and no significant difference being observed in the 3–4‐years time frame (OR 1.25; p = 0.09). Reduced odds were seen again in the 4–5‐years period (OR 0.51; 95% CI 0.35–0.73; p = 0.0002), which was also accompanied by a small negative risk difference. Laryngeal spasm showed a similar pattern, with lower odds observed early (0–1 years; OR 0.75; 95% CI 0.64–0.88; p = 0.0003) but increased odds at the 1–2‐years (OR 2.39; 95% CI 1.75–3.25; p < 0.0001), 2–3‐years (OR 2.79; 95% CI 1.93–4.04; p < 0.0001), and 3–4‐years intervals (OR 1.97; 95% CI 1.25–3.10; p = 0.003). By the 4–5‐years period, no significant association remained (OR 0.83; p = 0.49). Risk differences were small across all intervals but remained statistically significant for all comparisons except the 4–5‐years period. A summary of the association between COVID‐19 exposure and the odds of developing a new‐onset laryngeal dysfunction is presented in Table 3. TABLE 3COVID‐19 is associated with an increased incidence of new‐onset laryngeal dysfunction, including chronic cough, dysphagia, voice disorders, vocal fold paralysis, and laryngeal spasm, compared with uninfected controls.Odds ratios and risk differences of laryngeal dysfunction following COVID‐19 infection vs. non‐infected controls stratified by time interval after propensity score matchingDiagnosisTime intervalOdds ratio95% CIRisk difference (%)95% CI p Chronic cough (R05.3)0–1 years5.645.38–5.840.630.62–0.64< 0.0001*1–2 years7.126.68–7.600.330.32–0.34< 0.0001*2–3 years6.436.00–6.900.250.24–0.26< 0.0001*3–4 years3.973.67–4.290.120.11–0.13< 0.0001*4–5 years1.221.11–1.340.010.004–0.01< 0.0001*Aphagia and dysphagia (R13)0–1 years1.581.55–1.610.540.52–0.56< 0.0001*1–2 years2.712.62–2.810.360.34–0.37< 0.0001*2–3 years2.442.34–2.540.250.24–0.26< 0.0001*3–4 years1.691.61–1.780.100.09–0.11< 0.0001*4–5 years0.680.64–0.83−0.04−0.04 to −0.03< 0.0001*Voice and resonance disorders (R49)0–1 years1.181.14–1.230.050.04–0.06< 0.0001*1–2 years3.253.03–3.480.120.11–0.13< 0.0001*2–3 years2.752.55–2.980.080.07–0.08< 0.0001*3–4 years1.941.77–2.120.040.03–0.04< 0.0001*4–5 Years0.770.68–0.86−0.01−0.01 to −0.004< 0.0001*Paralysis of vocal cords and larynx (J38.0)0–1 year0.720.65–0.79−0.01−0.02 to −0.01< 0.0001*1–2 years2.171.79–2.640.010.01–0.01< 0.0001*2–3 years1.941.55–2.410.010.004–0.01< 0.0001*3–4 years1.250.96–1.630.0010.00–0.0030.094–5 years0.510.35–0.73−0.002−0.003 to −0.0010.0002*Laryngeal spasm (J38.5)0–1 years0.750.64–0.88−0.004−0.007 to −0.0020.0003*1–2 years2.391.75–3.250.0040.003–0.005< 0.0001*2–3 years2.791.93–4.040.0030.002–0.005< 0.0001*3–4 years1.971.25–3.100.0010.00–0.0020.003*4–5 years0.830.48–1.420.00−0.001 to 0.000.49 Note: Risk peaks 1–2 years after infection for most outcomes and is influenced by factors such as hospitalization, mechanical ventilation, and vaccination status. These findings highlight the need for long‐term surveillance and evaluation of laryngeal symptoms in patients with prior COVID‐19 infection. * Indicates statistically significant difference compared to control group. COVID‐19 is associated with an increased incidence of new‐onset laryngeal dysfunction, including chronic cough, dysphagia, voice disorders, vocal fold paralysis, and laryngeal spasm, compared with uninfected controls. Note: Risk peaks 1–2 years after infection for most outcomes and is influenced by factors such as hospitalization, mechanical ventilation, and vaccination status. These findings highlight the need for long‐term surveillance and evaluation of laryngeal symptoms in patients with prior COVID‐19 infection. * Indicates statistically significant difference compared to control group. Sub‐Analyses In the 0–5‐years sub‐analysis, COVID‐19 was associated with a higher rate of developing several laryngeal disorders (Figure 2A). The strongest association was observed for chronic cough, with a hazard ratio (HR) of 5.33 (95% CI 5.19–5.48). Patients in the COVID‐19 cohort demonstrated a significantly increased rate of dysphagia (HR 1.75; 95% CI 1.73–1.78) and voice disorders (HR 1.63; 95% CI 1.59–1.67). The hazard of laryngeal spasm was modest but significantly increased among patients in the COVID‐19 group relative to controls (HR 1.16; 95% CI 1.03–1.32). In contrast, COVID‐19 was not associated with an increased rate of developing vocal cord paralysis (HR 0.95; 95% CI 0.88–1.02). Forest plots depicting adjusted hazard ratios (HRs) for the development of laryngeal dysfunction following COVID‐19 infection. (A) Compares the risk of laryngeal dysfunction between the COVID‐19 cohort and propensity score–matched controls. (B–D) Present subgroup analyses within the COVID‐19 cohort, comparing vaccinated versus unvaccinated patients (B), patients requiring hospitalization versus those not hospitalized (C), and patients requiring mechanical ventilation versus those not mechanically ventilated (D). HRs with 95% confidence intervals (CIs) were derived from multivariable Cox proportional hazards models. The vertical reference line at HR = 1 indicates no association; HRs greater than 1 indicate an increased rate of developing the disorder. In the sub‐analysis comparing vaccinated and unvaccinated individuals with COVID‐19, vaccination status was associated with modest differences in the rate of developing long‐term laryngeal disorders (Figure 2B). The hazard of developing chronic cough was increased in vaccinated individuals compared with unvaccinated individuals (HR 1.36; 95% CI 1.25–1.49). A similar pattern was observed for voice disorders, with vaccinated patients demonstrating a higher rate these disorders (HR 1.22; 95% CI 1.06–1.39). In contrast, vaccination status was not associated with elevated likelihood of dysphagia (HR 0.99; 95% CI 0.92–1.06), vocal cord paralysis (HR 1.30; 95% CI 0.85–1.98), and laryngeal spasm (HR 1.03; 95% CI 0.49–2.15). In the sub‐analysis comparing hospitalized versus non‐hospitalized COVID‐19 patients, several patterns of laryngeal dysfunction development emerged (Figure 2C). Hospitalized patients demonstrated significantly lower rates of developing chronic cough (HR 0.68; 95% CI 0.64–0.72). In contrast, the hazard of dysphagia was significantly greater among hospitalized patients, with a higher than 2.5‐fold increased risk of onset relative to non‐hospitalized patients (HR 2.63; 95% CI 2.54–2.72). Hospitalization was also associated with high rates of voice disorders (HR 1.15; 95% CI 1.06–1.25) and vocal cord paralysis (HR 2.09; 95% CI, 1.68–2.60). There was no significant difference in the hazard of developing laryngeal spasm between the hospitalized and non‐hospitalized patients (HR 1.30; 95% CI 0.84–2.04). In the sub‐analysis comparing mechanically ventilated versus non‐ventilated COVID‐19 patients, invasive ventilatory support was associated with increased hazard of developing laryngeal disorders (Figure 2D). Mechanical ventilation was associated with lower rates of new onset chronic cough (HR 0.45; 95% CI 0.37–0.57). In contrast, mechanically ventilated patients had a higher time‐dependent probability of developing vocal cord paralysis, which showed a greater than 9‐fold increase in risk of new onset paralysis (HR 9.35; 95% CI 5.96–14.65). The rates of developing dysphagia and voice disorders were increased, with HRs of 5.26 (95% CI 4.83–5.72) and 4.45 (95% CI 3.68–5.40), respectively. Discussion This population‐scale investigation demonstrates that a history of COVID‐19 is associated with new‐onset laryngeal disorders, including chronic cough, dysphagia, voice disorders, vocal cord paralysis, and laryngeal spasm, compared to matched controls. The temporal patterns indicate a delayed emergence of laryngeal dysfunction after infection, with elevated odds persisting for several years and then generally declining, suggesting sustained but gradually resolving vulnerability. These findings underscore the substantial and prolonged impact of the association between COVID‐19 and laryngeal function and morbidity beyond acute illness. A key strength of this study is the detailed temporal resolution of heightened risk. Most laryngeal outcomes peaked in the 1–2‐years period after COVID‐19 diagnosis, with odds decreasing towards or below baseline by 4–5 years, apart from a more prolonged increase for chronic cough. Observed trends suggest a mechanism of persistent but gradually reversible injury. Overall, this supports the clinical relevance of the initial elevation of laryngeal dysfunction post COVID‐19. Subgroup analyses indicate that vaccination, hospitalization, and mechanical ventilation modify the risk of specific laryngeal outcomes following COVID‐19. Laryngeal dysfunction has been described in both severe and mild COVID‐19, with non‐hospitalized patients also demonstrating long‐term symptoms [12]. Mechanistically, COVID‐19 affects the larynx through direct viral neurotropism affecting vagal or glossopharyngeal nerves, leading to neuropathic cough or dysphonia [24, 31]. Additionally, systemic inflammation and prolonged cough could lead to lasting disruption of normal tissue function [32, 33, 34]. These findings suggest that in non‐hospitalized, non‐intubated patients, the dysfunction is most likely due to neuroinflammation. Treatment interventions also increase risk, including airway trauma and recurrent laryngeal nerve injury secondary to intubation, potentially causing vocal cord paralysis or dysphagia [13, 35, 36, 37]. Furthermore, prolonged ICU care and extended airway instrumentation can cause laryngeal edema, granulomas, and neuropathy, while high‐dose corticosteroids are associated with neuromuscular weakness and neuropathic complications [35, 38, 39]. Consistent with these mechanisms, hospitalization and mechanical ventilation were associated with higher rates of dysphagia, voice disorders, and vocal cord paralysis, suggesting important contributions from post‐ICU and instrumentation‐related injury in severe disease, while viral and inflammatory effects likely predominate in milder cases. Importantly, although reported in specialty cohorts, our 0–5‐years analysis found no increased hazard of vocal cord paralysis after COVID‐19, suggesting cases are largely limited to higher‐acuity populations. Chronic cough demonstrated an inverse relationship with disease severity, with lower rates among hospitalized and mechanically ventilated patients. These findings align with prior reports on chronic cough following COVID‐19 [12]. Studies evaluating post‐intubation laryngeal injury indicate chronic cough is not a consistently reported complication of endotracheal intubation, suggesting chronic cough following COVID‐19 is unlikely to arise from airway trauma alone [40]. Instead, chronic cough is understood as a manifestation of neuroinflammatory or neurotropic secondary to COVID‐19, consistent with models of post‐viral vagal neuropathy and sensory hypersensitivity [32]. One plausible explanation for this study's findings is that patients requiring ICU‐level care, who often receive antiviral medications, corticosteroids, and immunomodulatory agents, may experience reduced neuroinflammation and cough‐reflex hypersensitivity, lowering the risk of transitioning to a chronic cough phenotype [41, 42]. Differences in follow‐up and diagnostic coding between hospitalized and non‐hospitalized patients may also contribute. Individuals recovering from mild disease are more likely to seek outpatient care, where chronic cough is often evaluated and coded as a primary complaint [43]. In contrast, post‐hospitalization care for severe COVID‐19 often prioritized major functional or structural sequelae (e.g., respiratory failure, dysphagia, airway injury), which may overshadow documentation of chronic cough [44, 45]. Together, these mechanisms may contribute to the observed inverse association between disease severity and chronic cough incidence in this cohort. Interestingly, prior vaccination was associated with higher rates of chronic cough and voice disorders in the COVID‐19 cohort. This contrasts with most published studies showing a protective effect of vaccination against long COVID, although none have specifically examined its isolated impact on chronic cough or dysphonia [46]. Vaccines against viral infections function by eliciting an adaptive immune response, which can produce transient systemic inflammatory signaling that, in susceptible individuals, may theoretically contribute to neuroinflammatory pathways implicated in laryngeal dysfunction following COVID‐19 [47]. These findings may reflect unmeasured confounding and should therefore be interpreted cautiously. Potential explanations include differences in patient demographics or comorbidities, variant‐specific effects, healthcare‐seeking or reporting bias, and rare immune‐mediated mechanisms that may exacerbate cough or vocal impairment after breakthrough infection. Further studies are needed to determine whether these associations reflect true causal effects or are driven by confounding or selection biases. This study is constrained by several important limitations. Reliance on ICD‐coded diagnoses from routine clinical care may under‐capture cases and underestimate true outcome prevalence. Variability in coding practices, healthcare access, and documentation across participating institutions may introduce misclassification, including undocumented COVID‐19. Posterior glottic stenosis after prolonged intubation can mimic vocal fold paralysis, potentially overestimating ICD‐coded paralysis in mechanically ventilated patients. Incomplete and non‐uniformly available data within TriNetX, particularly regarding disease course and treatment details, may contribute to cohort heterogeneity. Finally, variability in data aggregation, care environments, and healthcare utilization may limit the generalizability of these findings. Despite these limitations, the consistency of results with plausible pathophysiologic mechanisms and prior smaller studies supports the validity and clinical relevance of the observed associations between COVID‐19 and long‐term laryngeal dysfunction. Conclusion Post‐COVID laryngeal dysfunction appears to be a real and prolonged phenomenon, with COVID‐19 survivors experiencing increased odds of developing laryngeal disorders, particularly in the first few years after infection. These effects likely arise secondary to a combination of iatrogenic and viral factors. Clinicians should recognize these risks as part of the long COVID syndrome and consider appropriate evaluation and management for affected patients. This retrospective cohort study demonstrates that COVID‐19 is associated with a significantly higher incidence of new‐onset chronic cough, dysphagia, voice disorders, vocal cord paralysis, and laryngeal spasm compared to matched controls over multiple years. The observed temporal patterns and persistent excess risk highlight the importance of ongoing surveillance and clinical management for post‐COVID laryngeal sequelae. Future studies are needed to clarify mechanisms, long‐term trajectories, and strategies for prevention and recovery in diverse populations. Funding The authors have nothing to report. Conflicts of Interest The authors declare no conflicts of interest. Supporting information Table S1: Baseline and propensity score matched (PSM) demographic characteristics for the sub‐analyses of the COVID‐19 cohort for the following subgroups: vaccinated versus unvaccinated, requiring hospitalization versus not requiring hospitalization, and requiring mechanical ventilation versus not requiring mechanical ventilation. Categorical variables are shown as counts with percentages in parentheses; continuous variables are reported as mean ± standard deviation and signified by a “*”.